The Global Pre-Clinical Imaging Market size was USD 915.49 Million in 2022 and it is expected to grow to USD 1421.05 Million in 2030 with a CAGR of 5.65% in the 2022-2030 period.
Global Preclinical Imaging Market: Overview
Pre-Clinical Imaging refers to the visualization of living animals for research purposes such as drug development and others. Pre-Clinical Imaging enables researchers to observe changes at the organ, tissue, cell or molecular levels. Imaging systems are primarily categorized into Morphological/Anatomical and primary molecular imaging techniques.
Key Insights
- As per the analysis done by our research analyst, the Global Pre-Clinical Imaging Market is estimated to grow with a CAGR 5.65% over the forecast period (2022-2030).
- In terms of revenue, the Global Preclinical Imaging Market size was valued at USD 915.49 million in 2022 and is estimated to grow to around USD 1421.05 billion in 2030.
- Due to various driving factors, the Pre-Clinical Imaging Market is predicted to grow at significant rate. Increase in demand for non-invasive small imaging techniques is the leading key factor.
- Based on the Product Segmentation, optical imaging segment dominated the market and took the major revenue share of 15.7% in 2021.
- Based on the Reagents Segmentation, Preclinical Optical Imaging reagent segment is likely to dominate the market share.
- Based on the End User Analysis, The Pharmaceutical & Biotechnology Companies hold a dominant position.
- By Regional Analysis, North America contributes major share in the market.
COVID-19 Impact:
COVID-19 has made a positive impact on the Preclinical Imaging Market. As the infection was spreading at a speedy rate and no effective drug was available for the treatment. Many hospitals and clinics were transformed to treat the patients diagnosed with COVID-19 to by increasing the number of beds. On the other hand, the preclinical imaging market has witnessed positive growth owing to an increase in the number of clinical trials for studying the efficacy and safety of various COVID-19 drugs, by researchers, pharmaceutical & biotech. Companies, and government institutes, the market witnessed positive growth.
Preclinical Imaging Market Dynamics:
Driving factors:
- Higher prevalence of chronic diseases: Sedentary lifestyles coupled with stress and bad habits has led to increase in number of chronic diseases worldwide. According to WHO, the global prevalence of chronic diseases increased by 57% in 2020 and due to an increase in the population density, it is likely to increase further in coming future. This has led to increasing in a number of people falling ill and thereby increasing the need for preclinical Imaging techniques.
- Increasing Demand for non-invasive small animal imaging techniques: Compared with the traditional invasive techniques, non-invasive small animal imaging techniques allow monitoring the diseases and responses to external substances in a temporal and spatial manner, thereby allowing a greater amount of information to be derived from a smaller number of animals.
- A growing number of Public-private initiatives & funding to support preclinical Imaging: There has been an increase in the number of public-private initiatives & funding to support preclinical imaging techniques. This is mainly because of the diverse patient pool and the need to cater to their demands in an optimal manner. The rise of various patient organizations, and health or charity organizations are helping patients to cope with the economic constraints as far as diagnosis and treatment is concerned. This has led to an increase in the number of preclinical imaging trials.
Restraints:
- Strict Government regulations: The strict government regulations regarding the animals under the trial concerning their health and safety is a major hindrance to the growth of the preclinical imaging market.
- High Initial Cost: High installation & operational cost of the preclinical imaging equipment, leads to higher rates of diagnosis via these techniques. Which not everyone can afford. This is another growth limiting factor.
Opportunities:
Exploring the untapped and emerging markets is a growth opportunity. The healthcare infrastructure is improving day by day along with a rising number of diseases and unmet healthcare needs, this has resulted in an increase in research and development activities. This serves as an opportunity factor for the market to grow. One may devise minimal invasive techniques which are more user-friendly in nature.
Preclinical Imaging Market Scope:
|
Attribute
|
Details
|
|
Market Size in 2022
|
USD 915.49 million
|
|
Estimated Market Size in 2030
|
USD 1421.05 million
|
|
CAGR Growth Rate
|
5.65%
|
|
Base Year
|
2022
|
|
Forecast Years
|
2023-2030.
|
|
Major Regions Covered
|
- North America
- Europe
- Asia Pacific
- Latin America
- The Middle East & Africa
|
|
Companies Covered
|
PerkinElmer, Inc., Bruker Corporation, FUJIFILM Holdings Corporation, Siemens A.G., General Electric (GE)Mediso Ltd, MILabs B.V., M.R.Solutions, LI-COR Biosciences, Aspect Imaging, TriFoil Imaging, Mitlenyi Biotech GmbH.
|
|
Report Coverage
|
Revenue Forecast, Company Share, Competitive Landscape, Growth Factors, Restraints, Opportunities, Value Chain Analysis, Porter’s Five Forces Analysis, Patent Analysis, Market Attractiveness Analysis by Segments
|
Preclinical Imaging Market: Segmentation
- Based on Product: The Optical Imaging techniques dominate the market growth. Multimodal imaging segment is also projected to show significant growth in the coming years. Technological advances have resulted in the development of integrated systems that include molecular and anatomical digital imaging systems, allowing multiple screening in a single unit, these new generation devices with integrated imaging technologies are expected to drive the growth of the multi-modal imaging devices market in preclinical studies.
- Based on Reagent: Reagents segment will also continue to grow in the coming years. Increased digitalization in the field has provided an interface that is user-friendly and it is finding major application in the field of oncology research. Preclinical optical imaging reagents is expected to the contribute largest share of the market.
- By End User Analysis: The market is segmented into pharmaceutical & biotechnology companies, Government & Academic Research Institutes, and Contract research organizations. Among these, the pharmaceutical & biotechnology companies are dominating the market growth.
Regional Insights:
North America dominates the market share due to the presence of key players, technological advancement in the field of optical imaging, and a rise in demand for non-invasive techniques. Asia Pacific likely to register the fastest growth during the forecast period, owing to the large population base, constant expenditure on improving healthcare facilities, and higher prevalence of chronic diseases in the region. Europe is expected to add substantial growth to the market.
Competitive Analysis:
Global Preclinical Imaging market key players include PerkinElmer, Inc., Bruker Corporation, FUJIFILM Holdings Corporation, Siemens A.G., General Electric (GE)Mediso Ltd, MILabs B.V., M.R.Solutions, LI-COR Biosciences, Aspect Imaging, TriFoil Imaging, Mitlenyi Biotech GmbH.
Recent Developments:
- October 2021: MILabs launched the seventh-generation advanced imager under the new ownership of Rikago Group.
- November 2021: Bruker Corporation acquired MOLECULES, N.V. a dynamic innovator in benchtop preclinical nuclear imaging system.
Global Preclinical Imaging Market Segment as follows:
by Product
- PET/SPECT
- Multi-modal Imaging
- CT
- MRI
- Ultrasound
- Photoacoustic Imaging
by Reagents
- Preclinical Optical Imaging Reagents
- Preclinical Nuclear Imaging Reagents
- Preclinical MRI Contrast Agents
- Preclinical Ultrasound Contrast Agents
- Preclinical CT Contrast Agents
by End Users
- Biotech Companies
- Pharmaceutical Companies
- Research Institutes
Frequently Asked Questions (FAQs):
Which is the leading segment in the market?
Among Modalities, Optical Imaging is the leading segment in the market.
What are the key factors driving the market?
Growing number of chronic diseases coupled with the increase in number of clinical trials and funding for the R&D are the driving factors for the market.
Which region will contribute notably towards the Preclinical Imaging Market growth?
North America contributes notably towards the Preclinical Imaging Market.
What are the key players in Preclinical Imaging Technology Company?
PerkinElmer
Bruker Corporation
Siemens A.G.
General Electric (GE)
FUJIFILM Holdings Corporation
Mediso Ltd
MILabs B.V.
MR. Solutions
LI-COR Biosciences
Aspect Imaging
TriFoil Imaging
Mitlenyi Biotech GmbH